
Glenn Haugeberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6835664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs. BMC Health Services Research, 2022, 22, 48.	2.2	11
2	Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life. Rheumatology International, 2022, 42, 669-682.	3.0	8
3	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS ONE, 2022, 17, e0266816.	2.5	6
4	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. Rheumatology and Therapy, 2022, 9, 1171-1179.	2.3	2
5	Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic. Scientific Reports, 2022, 12, 8283.	3.3	1
6	Incidence Trends and Mortality of Giant Cell Arteritis in Southern Norway. Arthritis Care and Research, 2021, 73, 409-414.	3.4	16
7	Physical and Psychosocial Burden of Psoriatic Arthritis: Longitudinal Data From a Populationâ€Based Study in Norway. Arthritis Care and Research, 2021, 73, 138-145.	3.4	16
8	Adiposity and Physical Activity as Risk Factors for Developing Psoriatic Arthritis: Longitudinal Data From a Populationâ€Based Study in Norway. Arthritis Care and Research, 2021, 73, 432-441.	3.4	19
9	Increased proportion of comorbidities but no deterioration of sexual quality of life during a 5-year follow-up in patients with axial spondyloarthritis in the biologic treatment era. Rheumatology, 2021, 60, 4112-4120.	1.9	2
10	Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. Rheumatology, 2021, 60, 4958-4971.	1.9	12
11	Incidence Trends and Mortality of Giant Cell Arteritis in Southern Norway. , 2021, 73, 409.		1
12	Decentralizing healthcare in Norway to improve patient-centered outpatient clinic management of rheumatoid arthritis – a conceptual model. BMC Rheumatology, 2021, 5, 43.	1.6	7
13	No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5Âyears in ordinary outpatient clinics in the biological treatment era. Quality of Life Research, 2020, 29, 99-107.	3.1	9
14	Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Research and Therapy, 2020, 22, 198.	3.5	31
15	Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open, 2020, 6, e001223.	3.8	21
16	Impact of Highâ€Intensity Interval Training on Disease Activity and Disease in Patients With Psoriatic Arthritis: A Randomized Controlled Trial. Arthritis Care and Research, 2019, 71, 530-537.	3.4	32
17	Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988397.	2.7	10
18	Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era. Journal of Rheumatology, 2019, 46, 1075-1083.	2.0	7

#	Article	IF	CITATIONS
19	FRI0439â€PERCEIVED INFLUENCE OF HEALTH STATUS ON SEXUAL ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS IS ASSOCIATED WITH MUSCULOSKELETAL MANIFESTATIONS BUT NOT WITH PSORIASIS SKIN MANIFESTATIONS. , 2019, , .		1
20	FRIO094â€LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG. , 2019, , .		0
21	SAT0146â€COMPARING DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS BOTH ETANERCEPT NAÃ⁻VE AND NON-MEDICAL SWITCH PATIENTS WITH ETANERCEPT REFERENCE DRUG IN A NORWEGIAN OUT-PATIENT CLINIC. PRELIMINARY RESULTS FROM A MULTI-CENTER STUDY. , 2019, , .		0
22	Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-TrÃ,ndelag Health Study (HUNT). RMD Open, 2018, 4, e000630.	3.8	8
23	Less periprosthetic bone loss following the anterolateral approach to the hip compared with the direct lateral approach. Monthly Notices of the Royal Astronomical Society: Letters, 2018, 89, 23-28.	3.3	8
24	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open, 2018, 4, e000631.	3.8	20
25	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Research and Therapy, 2018, 20, 160.	3.5	16
26	Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. Annals of the Rheumatic Diseases, 2018, 77, 1290-1294.	0.9	21
27	Digital X-ray radiogrammetry and its sensitivity and specificity for the identification of rheumatoid arthritis-related cortical hand bone loss. Journal of Bone and Mineral Metabolism, 2017, 35, 192-198.	2.7	15
28	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. Journal of Rheumatology, 2017, 44, 431-436.	2.0	18
29	Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Annals of the Rheumatic Diseases, 2017, 76, 708-711.	0.9	45
30	Bone mineral density in patients with psoriatic arthritis: data from the Nord-TrÃ,ndelag Health Study 3. RMD Open, 2017, 3, e000413.	3.8	9
31	Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Annals of the Rheumatic Diseases, 2017, 76, 1906-1910.	0.9	162
32	The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis. BMC Musculoskeletal Disorders, 2017, 18, 328.	1.9	20
33	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open, 2016, 2, e000302.	3.8	57
34	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Annals of the Rheumatic Diseases, 2016, 75, 2108-2113.	0.9	40
35	Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 1622-1630.	2.0	49
36	The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?. Rheumatology, 2016, 55, 66-70.	1.9	203

GLENN HAUGEBERG

#	Article	IF	CITATIONS
37	On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-TrÃ,ndelag Health Study. Annals of the Rheumatic Diseases, 2016, 75, 819-824.	0.9	61
38	Surgery for lumbar spinal stenosis in patients with rheumatoid arthritis: A multicenter observational study. European Journal of Rheumatology, 2016, 3, 56-60.	0.6	6
39	Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Research and Therapy, 2015, 17, 219.	3.5	56
40	Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study. Journal of Rheumatology, 2015, 42, 2279-2287.	2.0	27
41	Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-TrÃ,ndelag Health Study (HUNT). Annals of the Rheumatic Diseases, 2015, 74, 60-64.	0.9	42
42	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. PLoS ONE, 2015, 10, e0123582.	2.5	94
43	Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskeletal Disorders, 2014, 15, 289.	1.9	49
44	Exploring the relationship between bone density and severity of distal radius fragility fracture in women. Journal of Orthopaedic Surgery and Research, 2014, 9, 57.	2.3	13
45	Lyme arthritis in Southern Norway - an endemic area for Lyme Borreliosis. BMC Infectious Diseases, 2014, 14, 185.	2.9	8
46	Mortality after Distal Radius Fracture in Men and Women Aged 50 Years and Older in Southern Norway. PLoS ONE, 2014, 9, e112098.	2.5	24
47	Hand Bone Loss in Patients with Psoriatic Arthritis: Posthoc Analysis of IMPACT II Data Comparing Infliximab and Placebo. Journal of Rheumatology, 2013, 40, 1344-1348.	2.0	16
48	Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clinical and Experimental Rheumatology, 2013, 31, 409-14.	0.8	24
49	Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs. Modern Rheumatology, 2012, 22, 295-297.	1.8	1
50	Comparing 15D and SF-6D Performance in Fragility Wrist and Hip Fracture Patients in a Two-Year Follow-Up Case-Control Study. Value in Health, 2012, 15, 1100-1107.	0.3	5
51	Long-term in-vitro precision of direct digital X-ray radiogrammetry. Skeletal Radiology, 2011, 40, 1575-1579.	2.0	17
52	Value of digital Xâ€ray radiogrammetry in the assessment of inflammatory bone loss in rheumatoid arthritis. Arthritis Care and Research, 2011, 63, 666-674.	3.4	36
53	Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 184-187.	0.9	20
54	Two-year changes in quality of life in elderly patients with low-energy hip fractures. A case-control study. BMC Musculoskeletal Disorders, 2010, 11, 226.	1.9	27

GLENN HAUGEBERG

#	Article	IF	CITATIONS
55	Using hand bone mass measurements to assess progression of rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 79-87.	2.7	5
56	High disease activity is a predictor of cortical hand bone loss in post-menopausal patients with established rheumatoid arthritis: a 5-year multicentre longitudinal study. Rheumatology, 2010, 49, 1676-1682.	1.9	18
57	The Ability of Hand Digital X-Ray Radiogrammetry to Identify Middle-Aged and Elderly Women With Reduced Bone Density, as Assessed by Femoral Neck Dual-Energy X-Ray Absorptiometry. Journal of Clinical Densitometry, 2010, 13, 418-425.	1.2	16
58	Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. Arthritis Research and Therapy, 2009, 11, R103.	3.5	36
59	Short-Time In Vitro and In Vivo Precision of Direct Digital X-ray Radiogrammetry. Journal of Clinical Densitometry, 2009, 12, 17-21.	1.2	25
60	Imaging of metabolic bone diseases. Best Practice and Research in Clinical Rheumatology, 2008, 22, 1127-1139.	3.3	32
61	Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts?. Nature Clinical Practice Rheumatology, 2008, 4, 402-403.	3.2	16
62	Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1513-1517.	0.9	41
63	Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Research and Therapy, 2007, 9, R81.	3.5	66
64	Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis. Archives of Internal Medicine, 2005, 165, 1293.	3.8	103
65	Value of Dual-Energy X-Ray Absorptiometry as a Diagnostic and Assessment Tool in Early Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2005, 31, 715-728.	1.9	13
66	Vertebral Deformities in Rheumatoid Arthritis. Archives of Internal Medicine, 2004, 164, 420.	3.8	129
67	Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: The Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis and Rheumatism, 2003, 49, 209-215.	6.7	89
68	Effects of rheumatoid arthritis on bone. Current Opinion in Rheumatology, 2003, 15, 469-475.	4.3	84
69	Bone loss in patients with rheumatoid arthritis: Results from a population-based cohort of 366 patients followed up for two years. Arthritis and Rheumatism, 2002, 46, 1720-1728.	6.7	130
70	Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis and Rheumatism, 2000, 43, 522.	6.7	616
71	Reduced bone mineral density in male rheumatoid arthritis patients: Frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo county rheumatoid arthritis register. Arthritis and Rheumatism, 2000, 43, 2776-2784.	6.7	101